Taken together, the ASO studies point to the ability through selective reductions in APP and Rab5 gene expression to rescue significant defects in the ELN, cellular events impacted by ELN dysregulation, and markers of DS‐AD‐linked phenotypes. This evidence concerns the gene RAB5A and Alzheimer disease.